Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK)
- Previous Close
2.170 - Open
2.170 - Bid 2.060 x --
- Ask 2.150 x --
- Day's Range
2.040 - 2.170 - 52 Week Range
1.210 - 2.180 - Volume
8,000 - Avg. Volume
188,949 - Market Cap (intraday)
1.149B - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
5.69 - EPS (TTM)
0.360 - Earnings Date Aug 14, 2025 - Aug 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 24, 2025
- 1y Target Est
--
Jilin Province Huinan Changlong Bio-pharmacy Company Limited manufactures and distributes Chinese medicines and pharmaceutical products in the People's Republic of China. The company provides Edaravone injection, compound brain comfort capsules, haikun kidney hi capsules, cefpirome sulfate for injections, Cefpiramide for injections, anti-bone hyperplasia tablets, Lysine zinc gluconate tablets, and Qianlie Guihuang Tablets. It markets its products under the Changlong and Qing Tong brands. The company also engages in the manufacture and distribution of beverages and prepackaged food. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Kowloon, Hong Kong.
www.jlchanglong.com745
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 8049.HK
View More
Performance Overview: 8049.HK
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 8049.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 8049.HK
View MoreValuation Measures
Market Cap
1.22B
Enterprise Value
710.89M
Trailing P/E
6.10
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.28
Price/Book (mrq)
0.69
Enterprise Value/Revenue
0.75
Enterprise Value/EBITDA
2.78
Financial Highlights
Profitability and Income Statement
Profit Margin
20.91%
Return on Assets (ttm)
4.76%
Return on Equity (ttm)
11.85%
Revenue (ttm)
881.16M
Net Income Avi to Common (ttm)
184.25M
Diluted EPS (ttm)
0.360
Balance Sheet and Cash Flow
Total Cash (mrq)
583.59M
Total Debt/Equity (mrq)
4.44%
Levered Free Cash Flow (ttm)
229.25M